RT Journal Article SR Electronic T1 Hydroxychloroquine for the management of COVID-19: Hope or Hype? A Systematic review of the current evidence JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.16.20068205 DO 10.1101/2020.04.16.20068205 A1 Umesh Devappa Suranagi A1 Harmeet Singh Rehan A1 Nitesh Goyal YR 2020 UL http://medrxiv.org/content/early/2020/04/22/2020.04.16.20068205.abstract AB Purpose The COVID-19 Pandemic has literally left the world breathless in the chase for Pharmacotherapy. With the vaccine approval likely more than a year away and novel drugs in early clinical trials, repurposing of existing drugs takes the center stage. A potential drug discussed both in geopolitical and global scientific community is hydroxychloroquine (HCQ). We intend to systematically weigh and analyze the existing evidence of HCQ in the light of published and pre-print data available so far.Methods PubMed Ovid MEDLINE, EMBASE, Google scholar databases and official clinical trial Registries of the United States, China, WHO ICTRP were electronically searched for studies for the use of HCQ in patients with COVID-19. Pre-proof article repositories like MedRxiv, BioRxiv, and ChemRxiv were also included in the search. The literature was critically appraised.Results Total 71 articles were available as of 15th April of which articles of relevance (three in-vitro studies, two open label non-randomized trials, two open label randomized control trials, one follow-up study, three reviews, ten short communications) and 88 clinical trials registered in three clinical trial registries were analyzed. HCQ seems to be efficient in inhibiting of SARS-CoV-2 in in-vitro cell lines; there is lack of strong evidence from human studies.Conclusions The in-vitro cell culture based data of viral inhibition does not suffice for the use of hydroxychloroquine in the patients with COVID-19. Currently literature shows inadequate, low level evidence in human studies. Scarcity of safety and efficacy data warrants medical communities, health care agencies and governments across the world against the widespread use of HCQ in COVID-19 prophylaxis and treatment, until robust evidence becomes available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was NOT funded by any institution or third party. There are no conflict of interests. No financial support was taken from any person or agencyAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available with the authors. we assert and agree for the same.